{"nctId":"NCT00615264","briefTitle":"Efficacy Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Patients","startDateStruct":{"date":"2005-09"},"conditions":["Type 1 Diabetes"],"count":457,"armGroups":[{"label":"DiaPep277","type":"EXPERIMENTAL","interventionNames":["Drug: DiaPep277"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"DiaPep277","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A diagnosis of type 1 diabetes for up to 3 months at screening\n* Insulin dependency\n* Fasting C-peptide levels \\>= 0.22 nmol/L\n* Presence of at least 1 of the diabetes-related autoantibodies (IA-2A, GAD or IA)\n\nExclusion Criteria:\n\n* Pregnancy or intent to conceive in the next 2 years\n* Significant diseases that could affect response to treatment, such as tumors, psychiatric disorders, substance abuse, severe allergies or diabetes-related complications.\n* Patient has immune deficiency or receives immuno-suppressive or cytotoxic drugs.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"45 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glucagon-stimulated C-peptide AUC at 24 Months","description":"Beta-cell function, measured as change in stimulated C-peptide secretion measured 0, 2, 6, 10 and 20 minutes post administration \\[area under the curve (AUC), 0-20 minutes\\] at Baseline and 24 months, during a glucagon stimulation test (GST). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.848","spread":"0.4666"},{"groupId":"OG001","value":"-4.348","spread":"0.4584"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mixed-meal Stimulated C-peptide AUC at 24 Months","description":"Beta cell function, measured as stimulated C-peptide secretion from 0 to 120 min post administration AUC, at baseline and 24 month measurements in a mixed-meal tolerance test (MMTT). The change in AUC was calculated per patient by subtracting the baseline AUC from the 24 month AUC.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.33","spread":"3.6884"},{"groupId":"OG001","value":"-43.24","spread":"3.5898"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":26,"n":225},"commonTop":["Nasopharyngitis","Influenza","Injury, Poisoning and Procedural Complications","Skin and Subcutaneous Tissue Disorders","Upper respiratory Tract Infection"]}}}